CONTROLLED-RELEASE LEVODOPA CARBIDOPA-25/100 (SINEMET CR-25/100) - PHARMACOKINETICS AND CLINICAL EFFICACY IN UNTREATED PARKINSONIAN-PATIENTS/

Authors
HAMMERSTAD JP WOODWARD WR NUTT JG GANCHER ST BLOCK GA CYHAN G
Citation
Jp. Hammerstad et al., CONTROLLED-RELEASE LEVODOPA CARBIDOPA-25/100 (SINEMET CR-25/100) - PHARMACOKINETICS AND CLINICAL EFFICACY IN UNTREATED PARKINSONIAN-PATIENTS/, Clinical neuropharmacology, 17(5), 1994, pp. 429-434
Citations number
12
Categorie Soggetti
Pharmacology & Pharmacy",Neurosciences
Journal title
Clinical neuropharmacology → ACNP
ISSN journal
03625664
Volume
17
Issue
5
Year of publication
1994
Pages
429 - 434
Database
ISI
SICI code
0362-5664(1994)17:5<429:CLC(C->2.0.ZU;2-A
Abstract
The pharmacokinetics of the clinically determined optimal dose of cont rolled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without pri or exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also comp ared. As predicted from the plasma half-life (1.7 +/- 0.3 h) and confi rmed by morning trough levels, levodopa did not accumulate when contro lled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/c arbidopa 50/200.